Despite the common assumption that adverse drug reactions only affect the kidney and liver, more than 600 medications inducing lung toxicity have been reported.1 Lungs are susceptible to toxicity due to their large surface
Newcells Biotech are excited to announce that they are Phase II contract winners of the NC3Rs-funded CRACK IT Challenge (named ImmuLiver). They have been awarded a further funding to continue development of
In 2014, the World Health Organisation (WHO) estimated that air pollution leads to 7 million deaths per year. This figure is more than the number of deaths from AIDS, malaria and tuberculosis
Newcells Biotech is pleased to announce the acquisition of intellectual property pertaining to the methodology for the differentiation of three-dimensional retinal organoids from human induced pluripotent stem cells (hiPSCs) from Newcastle University. The acquired technology will add to the growing portfolio of proprietary technologies that Newcells
The retina is the means through which most people primarily perceive the world and for children particularly, visual defects can affect educational, social and emotional development.1 The importance of retinal disease, in
Retinal toxicity is an adverse side effect that can cause (usually irreversible) deterioration of a person’s vision, when taking certain medication. This has been seen for example in people taking Hydroxychloroquine for Malaria due to toxicity to the retinal cells. The retinal pigmented epithelium (RPE) is
Newcells Biotech is pleased to announce that it has appointed Dr Frank Armstrong to its Board as a Non-executive Director. “Attracting an executive of Frank’s proven track-record and expertise is another significant
Retinitis pigmentosa (RP) is a group of degenerative disorders of the retina, caused by mutations in one of more than 60 genes, including the genes for making rhodopsin, pre-mRNA processing factors and usherin. The genes
Antibacterial resistance is an ever-increasing concern for today’s society. As more bacterial strains become resistant to greater numbers of antibiotics, we could see modern-day healthcare rewind back to the mid-1940’s, when antibiotics
Newcells Biotech are one of three Phase I contract winners of a challenge-led competition that funds collaborations between industry, academics and SMEs to solve business and scientific ‘Challenges’. The NC3Rs challenge (named ImmuLiver), sponsored by Sanofi
2018 has been a significant year for Newcells Biotech. We have secured substantial investment, launched new, ground-breaking products, attended global events and expanded our every growing team. Here are some of our defining moments
International Trade Mission – December 2018 Newcells Biotech CEO, Dr Mike Nicholds, and CSO, Prof Lyle Armstrong, are delighted to be taking part in a global trade mission hosted by the Department for International Trade and partially funded by the Northern Powerhouse. Dr Nicholds and Prof Armstrong will travel to Greater
